Are Proton Pump Inhibitors Contributing in Emerging New Hypertensive Population?
暂无分享,去创建一个
Monika Saini | Baiaan H. Alsaadi | Thakur Gurjeet Singh | Eman Shorog | S. A. Abutaily | Samrat Chauhan | Rohit Tayal | Sabina Yasmin | Maryam M Althubyani | Fatimah Aljohani | M. A. Alenazi | Mohammad Yousuf Ansari
[1] Shenglin Jiang,et al. The Efficacy and Safety of Proton Pump Inhibitors Combining Dual Antiplatelet Therapy in Patients with Coronary Intervention: A Systematic Review, Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials , 2023, Reviews in Cardiovascular Medicine.
[2] A. Eid,et al. Inflammation and hypertension: Underlying mechanisms and emerging understandings , 2023, Journal of cellular physiology.
[3] M. Kusumoto,et al. Monitoring of serum magnesium levels during long-term use of proton pump inhibitors in elderly japanese patients: is it really necessary or not? , 2022, Journal of pharmaceutical health care and sciences.
[4] C. Tack,et al. Hypomagnesemia and Cardiovascular Risk in Type 2 Diabetes , 2022, Endocrine reviews.
[5] Safeera Khan,et al. The Effects of Proton Pump Inhibitors in Acid Hypersecretion-Induced Vitamin B12 Deficiency: A Systematic Review (2022) , 2022, Cureus.
[6] K. Red-Horse,et al. Vascular endothelial cell development and diversity , 2022, Nature Reviews Cardiology.
[7] J. de Batlle,et al. Evolution of the consumption trend of proton pump inhibitors in the Lleida Health Region between 2002 and 2015 , 2022, BMC Public Health.
[8] Jin-fang Xu,et al. Updated Insights on Cardiac and Vascular Risks of Proton Pump Inhibitors: A Real-World Pharmacovigilance Study , 2022, Frontiers in Cardiovascular Medicine.
[9] M. Volpe,et al. Endothelial Dysfunction in Hypertension: Current Concepts and Clinical Implications , 2022, Frontiers in Medicine.
[10] Changhao Sun,et al. Association of dietary calcium, magnesium, sodium, and potassium intake and hypertension: a study on an 8-year dietary intake data from the National Health and Nutrition Examination Survey , 2021, Nutrition research and practice.
[11] Robert E. Cohen,et al. Association between proton pump inhibitors and periodontal disease severity , 2021, Clinical and experimental dental research.
[12] R. Memon,et al. Effects of Proton Pump Inhibitors on Serum Calcium Level: A Study on Rabbit Model , 2021, Journal of Pharmaceutical Research International.
[13] H. McNulty,et al. Associations of atrophic gastritis and proton-pump inhibitor drug use with vitamin B-12 status, and the impact of fortified foods, in older adults , 2021, The American journal of clinical nutrition.
[14] S. Bhatia,et al. Unravelling the involvement of gut microbiota in type 2 diabetes mellitus. , 2021, Life sciences.
[15] J. Linseisen,et al. Association of proton pump inhibitor use with endothelial function and metabolites of the nitric oxide pathway: A cross‐sectional study , 2021, Pharmacotherapy.
[16] O. Senn,et al. Potentially inappropriate proton-pump inhibitor prescription in the general population: a claims-based retrospective time trend analysis , 2021, Therapeutic advances in gastroenterology.
[17] R. Valera,et al. Adverse Effects Associated with Proton Pump Inhibitor Use , 2021, Cureus.
[18] M. Barbagallo,et al. Magnesium and Hypertension in Old Age , 2020, Nutrients.
[19] A. Anjankar,et al. Vitamin B12 - Do You Know Everything? , 2020, Journal of Evolution of Medical and Dental Sciences.
[20] Rajwinder Kaur,et al. Pleotropic Effects of Polyphenols in Cardiovascular System. , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[21] Ayaz Ahmad,et al. A retrospective study on prescribing pattern and cost analysis of proton‐pump inhibitors used among adults of Saudi Arabia , 2020 .
[22] J. Tanus-Santos,et al. Consistent gastric pH-dependent effects of suppressors of gastric acid secretion on the antihypertensive responses to oral nitrite. , 2020, Biochemical pharmacology.
[23] C. Sperati,et al. Drug-Induced Hypertension. , 2019, Endocrinology and metabolism clinics of North America.
[24] S. Ima-Nirwana,et al. Proton Pump Inhibitors and Fracture Risk: A Review of Current Evidence and Mechanisms Involved , 2019, International journal of environmental research and public health.
[25] J. Belizán,et al. Mechanisms Involved in the Relationship between Low Calcium Intake and High Blood Pressure , 2019, Nutrients.
[26] J. Tanus-Santos,et al. Nitrite-stimulated Gastric Formation of S-nitrosothiols As An Antihypertensive Therapeutic Strategy. , 2019, Current drug targets.
[27] A. Pottegård,et al. Use of proton pump inhibitors among Danish children: A 16‐year register‐based nationwide study , 2019, Basic & clinical pharmacology & toxicology.
[28] Avinash B. Kumar,et al. The risks of long-term use of proton pump inhibitors: a critical review , 2018, Therapeutic advances in drug safety.
[29] M. Iancu,et al. Drug-induced arterial hypertension – a frequently ignored cause of secondary hypertension: a review , 2018, Acta cardiologica.
[30] G. Corrao,et al. Use of proton pump inhibitors and risk of ischemic events in the general population. , 2018, Atherosclerosis.
[31] Xian Wang,et al. Homocysteine causes vascular endothelial dysfunction by disrupting endoplasmic reticulum redox homeostasis , 2018, Redox biology.
[32] Qingze Fan,et al. Changes in proton pump inhibitor prescribing trend over the past decade and pharmacists’ effect on prescribing practice at a tertiary hospital , 2018, BMC Health Services Research.
[33] Joshua W. Miller. Proton Pump Inhibitors, H2-Receptor Antagonists, Metformin, and Vitamin B-12 Deficiency: Clinical Implications. , 2018, Advances in nutrition.
[34] N. Ishimura,et al. Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use , 2018, Journal of neurogastroenterology and motility.
[35] M. Hlatky,et al. Long‐term use of proton pump inhibitors, dose–response relationship and associated risk of ischemic stroke and myocardial infarction , 2018, Journal of internal medicine.
[36] P. Bytzer,et al. Persistent severe hypomagnesemia caused by proton pump inhibitor resolved after laparoscopic fundoplication , 2017, World journal of gastroenterology.
[37] A. Mangoni,et al. Human dimethylarginine dimethylaminohydrolase 1 inhibition by proton pump inhibitors and the cardiovascular risk marker asymmetric dimethylarginine: in vitro and in vivo significance , 2017, Scientific Reports.
[38] Yong-Qing Wang,et al. A Review of the Novel Application and Potential Adverse Effects of Proton Pump Inhibitors , 2017, Advances in Therapy.
[39] G. Cheng,et al. Proton pump inhibitor monotherapy and the risk of cardiovascular events in patients with gastro‐esophageal reflux disease: a meta‐analysis , 2017, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.
[40] D. Peura,et al. 25 Years of Proton Pump Inhibitors: A Comprehensive Review , 2016, Gut and liver.
[41] A. Zullo,et al. Effective and safe proton pump inhibitor therapy in acid-related diseases – A position paper addressing benefits and potential harms of acid suppression , 2016, BMC Medicine.
[42] T. Card,et al. Proton pump inhibitor prescribing patterns in the UK: a primary care database study , 2016, Pharmacoepidemiology and drug safety.
[43] M. Bolanowski,et al. Effects of long-term administration of pantoprazole on bone mineral density in young male rats , 2016, Pharmacological reports : PR.
[44] E. Savarino,et al. Are proton pump inhibitors really so dangerous? , 2016, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[45] J. Cooke,et al. Proton Pump Inhibitors Accelerate Endothelial Senescence. , 2016, Circulation research.
[46] J. Hallas,et al. Use of proton-pump inhibitors among adults: a Danish nationwide drug utilization study , 2016, Therapeutic advances in gastroenterology.
[47] J. Cooke,et al. How May Proton Pump Inhibitors Impair Cardiovascular Health? , 2016, American Journal of Cardiovascular Drugs.
[48] J. Tanus-Santos,et al. Gastric S-nitrosothiol formation drives the antihypertensive effects of oral sodium nitrite and nitrate in a rat model of renovascular hypertension. , 2015, Free radical biology & medicine.
[49] F. Messerli,et al. Drug induced hypertension--An unappreciated cause of secondary hypertension. , 2015, European journal of pharmacology.
[50] M. Rodríguez-Moran,et al. Prevalence of Prehypertension in Mexico and Its Association With Hypomagnesemia. , 2015, American journal of hypertension.
[51] Y. Bae,et al. Association of Magnesium Intake with High Blood Pressure in Korean Adults: Korea National Health and Nutrition Examination Survey 2007–2009 , 2015, PloS one.
[52] P. Ganguly,et al. Role of homocysteine in the development of cardiovascular disease , 2015, Nutrition Journal.
[53] J. Toh,et al. Hypomagnesaemia associated with long-term use of proton pump inhibitors , 2014, Gastroenterology report.
[54] G. Panagopoulos,et al. Potential Costs of Inappropriate Use of Proton Pump Inhibitors , 2014, The American journal of the medical sciences.
[55] J. Pines,et al. Rising rates of proton pump inhibitor prescribing in US emergency departments. , 2014, The American journal of emergency medicine.
[56] Z. Kopczyński,et al. [Endothelial dysfunction in patients with primary hypertension and hyperhomocysteinemia]. , 2014, Postepy higieny i medycyny doswiadczalnej.
[57] D. Corley,et al. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. , 2013, JAMA.
[58] J. Tanus-Santos,et al. TEMPOL enhances the antihypertensive effects of sodium nitrite by mechanisms facilitating nitrite-derived gastric nitric oxide formation. , 2013, Free radical biology & medicine.
[59] N. Shah,et al. Unexpected Effect of Proton Pump Inhibitors: Elevation of the Cardiovascular Risk Factor Asymmetric Dimethylarginine , 2013, Circulation.
[60] J. Heidelbaugh. Proton pump inhibitors and risk of vitamin and mineral deficiency: evidence and clinical implications , 2013, Therapeutic advances in drug safety.
[61] S. Bu,et al. Daily calcium intake and its relation to blood pressure, blood lipids, and oxidative stress biomarkers in hypertensive and normotensive subjects , 2012, Nutrition research and practice.
[62] J. Tanus-Santos,et al. Increase in gastric pH reduces hypotensive effect of oral sodium nitrite in rats. , 2012, Free radical biology & medicine.
[63] J. Chenot,et al. Appropriateness of proton pump inhibitor recommendations at hospital discharge and continuation in primary care , 2012, International journal of clinical practice.
[64] D. Metz,et al. Proton pump inhibitors: are they overutilised in clinical practice and do they pose significant risk? , 2012, International journal of clinical practice.
[65] U. Förstermann,et al. Nitric oxide synthases: regulation and function. , 2012, European heart journal.
[66] M. Neves,et al. Magnesium and Vascular Changes in Hypertension , 2012, International journal of hypertension.
[67] J. Cooke,et al. DDAH says NO to ADMA. , 2011, Arteriosclerosis, thrombosis, and vascular biology.
[68] T. Cundy,et al. Proton pump inhibitors and severe hypomagnesaemia , 2011, Current opinion in gastroenterology.
[69] R. Jensen,et al. Association of Long-Term Proton Pump Inhibitor Therapy with Bone Fractures and Effects on Absorption of Calcium, Vitamin B12, Iron, and Magnesium , 2010, Current gastroenterology reports.
[70] J. Mackay,et al. Hypomagnesaemia due to proton-pump inhibitor therapy: a clinical case series. , 2010, QJM : monthly journal of the Association of Physicians.
[71] P. Sipponen,et al. Hypochlorhydric stomach: a risk condition for calcium malabsorption and osteoporosis? , 2010, Scandinavian journal of gastroenterology.
[72] P. Stover,et al. Vitamin B12 and older adults , 2010, Current opinion in clinical nutrition and metabolic care.
[73] V. Rodriguez,et al. Molecular mechanisms triggered by low-calcium diets , 2009, Nutrition Research Reviews.
[74] K. Insogna,et al. The Effect of Proton Pump-Inhibiting Drugs on Mineral Metabolism , 2009, The American Journal of Gastroenterology.
[75] T. Cundy,et al. Severe hypomagnesaemia in long‐term users of proton‐pump inhibitors , 2008, Clinical endocrinology.
[76] Aleksander S Popel,et al. Nitric oxide in the vasculature: where does it come from and where does it go? A quantitative perspective. , 2008, Antioxidants & redox signaling.
[77] Mark T. Gladwin,et al. The nitrate–nitrite–nitric oxide pathway in physiology and therapeutics , 2008, Nature Reviews Drug Discovery.
[78] James Spalding,et al. Proton Pump Inhibitor Utilization Patterns in Infants , 2007, Journal of pediatric gastroenterology and nutrition.
[79] P. Patel,et al. Role of Proton Pump Inhibitors in Calcium Absorption, Bone Resorption, and Risk of Hip Fracture , 2007 .
[80] T. Lüscher,et al. Nitric Oxide in Hypertension , 2006, Journal of clinical hypertension.
[81] C. O'Morain,et al. Review article: the long‐term use of proton‐pump inhibitors , 2005, Alimentary pharmacology & therapeutics.
[82] A. Murray,et al. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. , 2005, The American journal of medicine.
[83] N. Weiss. Mechanisms of increased vascular oxidant stress in hyperhomocys-teinemia and its impact on endothelial function. , 2005, Current drug metabolism.
[84] G. Werstuck,et al. Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease , 2004, Cell Death and Differentiation.
[85] P. Tsao,et al. Dimethylarginine Dimethylaminohydrolase Regulates Nitric Oxide Synthesis: Genetic and Physiological Evidence , 2003, Circulation.
[86] M. Orellana,et al. Homocysteine and Essential Hypertension , 2003, Journal of clinical pharmacology.
[87] S. Lentz,et al. Hyperhomocysteinemia, endothelial dysfunction, and cardiovascular risk: the potential role of ADMA. , 2003, Atherosclerosis. Supplements.
[88] J. Loscalzo,et al. Influence of Hyperhomocysteinemia on the Cellular Redox State – Impact on Homocysteine-Induced Endothelial Dysfunction , 2003, Clinical chemistry and laboratory medicine.
[89] R. Böger. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. , 2003, Cardiovascular research.
[90] S. Gallus,et al. Hospital use of acid‐suppressive medications and its fall‐out on prescribing in general practice: a 1‐month survey , 2003, Alimentary pharmacology & therapeutics.
[91] R. Böger. Association of Asymmetric Dimethylarginine and Endothelial Dysfunction , 2003, Clinical chemistry and laboratory medicine.
[92] K. Bønaa,et al. Relation between low calcium intake, parathyroid hormone, and blood pressure. , 2000, Hypertension.
[93] O. Chonan,et al. Effect of L-lactic acid on calcium absorption in rats fed omeprazole. , 1998, Journal of nutritional science and vitaminology.
[94] P. Whelton,et al. Hypertension , 1942, Nature Reviews Disease Primers.
[95] N. Shah,et al. Essential hypertension , 1942, Medical times.
[96] E. Savarino,et al. The appropriate use of proton pump inhibitors (PPIs): Need for a reappraisal. , 2017, European journal of internal medicine.
[97] C. Stefanadis,et al. The role of nitric oxide on endothelial function. , 2012, Current vascular pharmacology.
[98] C. Ponticelli,et al. Effect of gastric acid secretion on intestinal phosphate and calcium absorption in normal subjects. , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.